voltarol 140mg medicated plaster
novartis consumer health uk limited - diclofenac sodium - medicated plaster - 140mg - topical products for joint and muskular pain; antiinflammatory preparations, non-steroids for topical use - local symptomatic and short term treatment of pain in acute strains, sprains or bruises of the extremities following blunt trauma, e.g. sports injuries in adolescents from 16 years of age and adults
nicotinell fruity mint 1 milligram lozenges
novartis consumer health uk limited - nicotine bitartrate dihydrate - lozenges - 1 milligram - drugs used in nicotine dependence
nicotinell fruity mint 2 milligram lozenges
novartis consumer health uk limited - nicotine bitartrate dihydrate - lozenges - 2 milligram - drugs used in nicotine dependence
excedrin 250/250/65 milligram film coated tablet
novartis consumer health uk limited - acetylsalicylic acid, paracetamol, caffeine - film coated tablet - 250/250/65 milligram - analgesics and antipyretics
otrivine adult mucus relief menthol 0.1 %w/v nasal spray solution
novartis consumer health uk limited - xylometazoline hydrochloride - nasal spray solution - 0.1 %w/v
voltarol active 4% spray
novartis consumer health uk ltd - diclofenac sodium - cutaneous spray solution - 40mg/1gram
amlodipine/valsartan/hct novartis 10/320/25 amlodipine/valsartan/hydrochlorothiazide tablet blister pack
novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).
amlodipine/valsartan/hct novartis 10/160/25 amlodipine/valsartan/hydrochlorothiazide tablet blister pack
novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; crospovidone; microcrystalline cellulose; hypromellose; purified talc; iron oxide yellow; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).
amlodipine/valsartan/hct novartis 10/160/12.5 amlodipine/valsartan/hydrochlorothiazide tablet blister pack
novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; crospovidone; magnesium stearate; hypromellose; purified talc; iron oxide red; macrogol 4000; iron oxide yellow; titanium dioxide - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).
amlodipine/valsartan/hct novartis 5/160/25 amlodipine/valsartan/hydrochlorothiazide tablet blister pack
novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 160 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide yellow - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).